Navigation Links
Ameritox and Ingenuity Health Building Comprehensive Reference Database to Help Assess Medication Adherence in those with Serious Mental Illness
Date:8/14/2014

BALTIMORE, Aug. 14, 2014 /PRNewswire/ -- AmeritoxSM, the nation's leader in medication monitoring solutions, today launched a method to help assess medication adherence in behavioral health patients prescribed the antipsychotic drug Seroquel XR, one of the 40 best-selling medications in the U.S. This new method marks a critical step toward building a comprehensive reference database, providing behavioral health clinicians help in addressing the acute problem of medication non-adherence in those with serious mental illness.

Ameritox's Ingenuity Health service conducted research that allows it to provide additional information about whether a patient may be taking Seroquel XR correctly. By comparing normalized urine drug results against the results of patients clinically assessed as adherent, behavioral health centers and medical professionals will have more information as they manage and treat patients prescribed Seroquel XR.

"The singular problem of a lack of insight into whether a person is taking the medication prescribed has long been a barrier to helping those with serious mental illness," said Mike DeGeorge, Director of Medical Affairs for Ameritox and Ingenuity Health. "This method helps address the problem that behavioral health clinicians face with 50 percent of their patients: medication non-adherence."

Seroquel XR, a branded form of quetiapine, is the second antipsychotic medication for which Ingenuity Health has established a reference range for better assessing medication adherence. In March, Ingenuity Health introduced a reference range for Abilify, the nation's top-selling medication.

In developing these reference ranges, Ingenuity Health is building a database for comparing a patient's urine drug test results with those of a group of patients clinically assessed as adherent and taking the same medication. This database will expand Ameritox's exclusive Rx Guardian CDSM, which goes beyond traditional data gathering to provide analysis that can help clinicians address the growing problem of pain medication misuse, abuse and diversion.

Additional research is underway to develop similar reference ranges for other commonly prescribed antipsychotics.

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation's trusted leader in Pain Medication Monitoring SolutionsSM, Ameritox provides medical and business professionals with data-driven analysis and tailored solutions that can improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com

Follow Ameritox on Twitter: www.twitter.com/ameritox

Watch Ameritox on YouTube: www.youtube.com/ameritox

www.ingenuityhealth.com


'/>"/>
SOURCE Ameritox
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Ameritox Joins with Progressive Medical in Urine Drug Monitoring Network to Help Improve Care of Injured Workers
2. Ameritox Leadership Supports Lawmakers, Pain Practitioners and Patients Confronting Crisis in Pain Medication Abuse
3. Ameritox and Wake Forest University Form Research Partnership
4. Ameritox Appoints New CEO, Scott Walton
5. Bath Salts: With Dangerous Drug Use on the Rise, Ameritox Launches Critical New Test to Help Detect Designer Drug
6. Millennium Laboratories Wins Lawsuit: Ameritox Advertisements Regarding Rx Guardian and Rx Guardian CD Contain Literally False Statements
7. Ameritox Announces Educational Resources to Help Physicians Navigate Complex Compliance Issues
8. Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages
9. QIAGEN Offers Clinical Labs Early Access to New Ingenuity Solution for Streamlined Interpretation of Patient Sequencing Data
10. QIAGEN Significantly Expands its Offering of Assay Panels for Next-generation Sequencing (NGS) Complemented by Ingenuity Analysis and Interpretation Capabilities
11. Ingenuity Systems Announces Awardees of Grant Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... , June 24, 2016 ... has announced the addition of the " Global ... This report ... provides an updated review, including its applications in various ... total market, which includes three main industries: pharmaceutical and ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):